Loading clinical trials...

Anlotinib Retrospective Study for Esophageal Cancer | Clinical Trials | Clareo Health

COMPLETED

Anlotinib Retrospective Study for Esophageal Cancer

Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study

NCT05303740•Feng Wang

View on ClinicalTrials.gov

Summary

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Esophageal cancer diagnosed pathologically or clinically
•Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion Criteria

•None

Locations (1)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Key Dates

Start Date

January 1, 2019

Primary Completion Date

March 1, 2022

Completion Date

March 1, 2022

Last Updated

March 31, 2022

Enrollment

300

ACTUAL participants

Conditions

Esophageal Neoplasms

Interventions

Anlotinib

DRUG

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

NCT07035587

Lung NeoplasmsPancreatic Neoplasms+6 more

View study

RECRUITING

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

NCT05688176

Esophageal Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 31, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Anlotinib Retrospective Study for Esophageal Cancer

Inclusion Criteria

Exclusion Criteria

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Esophageal Cancer Multimodal Prehabilitation Study

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)